Did you know?

Jan 9, 2022 · Stephanie Spanos, [email protected], 608-556-4380. Exact Sciences Investor Contact: Megan Jones, [email protected], 608-535-8815. OncXerna Investor and Media Contact: Ashley R. Robinson, LifeSci Partners, LLC, [email protected]. [1]Chau, I. Phase 2 Study of Bavituximab, a First-in-class Antibody Targeting ... Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $602.5 million for the first quarter ended March 31, 2023, compared to $486.6 million for the same period of 2022. "Exact Sciences is changing the way cancer is detected and treated.Provides Access to Industry-Leading Sequencing Lab and Plans for 10-Year Partnership with National Cancer Research Leaders Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has entered into an agreement to acquire Ashion Analytics, LLC (Ashion) from The Translational Genomics Research Institute (TGen), an affiliate of … Exact Sciences’ products, services, mission, and people all work together to support early cancer detection and smarter treatment decisions. MADISON, Wis. and CAMBRIDGE, Mass., Oct. 27, 2020 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) and Thrive Earlier Detection Corp. ("Thrive"), a healthcare company dedicated to incorporating earlier cancer detection into routine medical care, today announced they have entered into a definitive agreement under which Exact …Exact Sciences’ products, services, mission, and people all work together to support early cancer detection and smarter treatment decisions.Discover real-time Exact Sciences Corporation Common Stock (EXAS) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Stay ahead with Nasdaq. Explore the tests that Exact Sciences offers for different types of cancer, based on innovative science and proven accuracy. Learn more about Cologuard and other tests. Jan 9, 2022 · Stephanie Spanos, [email protected], 608-556-4380. Exact Sciences Investor Contact: Megan Jones, [email protected], 608-535-8815. OncXerna Investor and Media Contact: Ashley R. Robinson, LifeSci Partners, LLC, [email protected]. [1]Chau, I. Phase 2 Study of Bavituximab, a First-in-class Antibody Targeting ... © Exact Sciences Corporation – 5505 Endeavor Lane - Madison, WI 53719 Powered By Q4 Inc. 5.122.0.3 5.122.0.3Exact Sciences delivers the promise and value of precision medicine with the Oncotype IQ® portfolio of genomic tests to help guide treatment for a variety of cancers. NEW! Patient Profile Navigator . Search Canada - English Brazil Canada - Français Deutschland France Ελλάδα Ireland Latin America Netherlands Spain Switzerland United Kingdom United …Exact Sciences values its current relationships with external recruitment vendors. If you are interested in learning more about partnering with us as an external recruitment vendor, please contact our Human Resources Department directly. Neither Exact Sciences Corporation nor any subsidiary or other related entity will be liable for any fees for any …Exact Sciences Corporation (NASDAQ:EXAS) Q2 2023 Earnings Call Transcript August 1, 2023 5:00 PM ET. Company Participants. Megan Jones - Vice President of Investor Relations

The building will serve as Exact Sciences' corporate headquarters from which the company will continue its work to eradicate colorectal cancer and combat other cancers through early detection. When complete in early 2020, the building will unite team members and departments currently dispersed across multiple sites in the Madison area.Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non …PreventionGenetics’ 20-year anniversary is one of several key milestones that Exact Sciences is celebrating in 2024. Its Cologuard® colorectal cancer screening test turns 10, and Oncotype DX® marks 20 years of providing breast cancer patients with life-changing guidance. Bobby Adamov, vice president of commercial rare disease at ...Mar 28, 2024 · MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, in collaboration with Mayo Clinic Comprehensive Cancer Center, reported on data showing high sensitivity and specificity for the non-endoscopic Oncoguard ® Esophagus test that is currently in development for the detection of esophageal adenocarcinoma (EAC) and its ... DENVER – Exact Sciences Corporation, a Madison, Wis.-based molecular diagnostics company, will pay $90,000 and furnish other relief to settle an age discrimination lawsuit filed by the U.S. Equal Employment Opportunity Commission (EEOC), the federal agency announced today.

Exact Sciences Corporation, Madison, USA. 2 Boston Biostatistics Research Foundation, Framingham, USA. 3 Mayo Clinic, Rochester, USA. PMID: 32054393; PMCID ... Explore the tests that Exact Sciences offers for different types of cancer, based on innovative science and proven accuracy. Learn more about Cologuard and other tests. Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $456.4 million for the third quarter ended September 30, 2021, compared to $408.4 million for the same period of 2020. "Exact Sciences is entering an exciting period for its pipeline, generating evidence to support innovative tests that will help defeat ……

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Exact Sciences Corporation - Investor Relati. Possible cause: Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening a.